• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Samsung Bioepis gets nod for sale of biosimilar drug in Europe

firstwordpharmaMarch 06, 2019

Tag: Samsung Bioepis , NOD , biosimilar drug

  • Samsung Bioepis has won European approval of a 420-mg dosage of Ontruzant, a biosimilar of Roche's Herceptin, The Korea Herald reported Tuesday.

  • The drugmaker previously gained clearance for the 150-mg dosage in 2017.

  • "There is demand for both 150 mg and 420 mg products in Europe," a company official remarked, adding "we expect to provide more treatment opportunities for patients by expanding our product portfolio."

Register as Visitor to CPhI China 2019!

Previous:Johnson & Johnson's Spravato garners FDA approval for treatment-resistant depression

Next:Novo Nordisk Pharma Ltd. partners with Health2Sync in Japan, bringing digital diabetes management to healthcare providers and patients

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Samsung Bioepis gets nod for sale of biosimilar drug in Europe | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Ganoderlactone D

Ganoderlactone D
Lipid nanoparticle drug manufacturing system/Nanodrug production system/MPE-P1 MICROFLUIDIC PREPARAT

Lipid nanoparticle drug manufacturing system/Nanodrug production system/MPE-P1 MICROFLUIDIC PREPARAT
Antibiotics aluminum cover plastic cover anodized aluminum cover

Antibiotics aluminum cover plastic cover anodized aluminum cover
Cyclopropylboronic acid methyliminodiacetic acid anhydride

Cyclopropylboronic acid methyliminodiacetic acid anhydride
12-O-Acetylganoderic acid θ

12-O-Acetylganoderic acid θ
Ganoderma spore powder

Ganoderma spore powder
4-AMINODIBENZOFURAN

4-AMINODIBENZOFURAN
Food ingredients 50% Reishi(Ganoderma lucidum) beta-D Glucan

Food ingredients 50% Reishi(Ganoderma lucidum) beta-D Glucan
23S-hydroxyl-11,15-dioxo-ganoderic acid DM

23S-hydroxyl-11,15-dioxo-ganoderic acid DM
Ganoderma Spore Oil

Ganoderma Spore Oil

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service